Page 24 - T Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

In this application note, Merck emphasizes the importance of contamination-free T cell culture media prepared through filter sterilization. The right filter membrane retains essential growth factors while removing contaminants. The Stericup ® filtration systems maintain protein integrity and minimize waste. The study examines repeated filtration of T cell media using Stericup filters, showing sustained T cell growth and function, aiding T cell therapy production.

BlueRock Therapeutics, a clinical stage cell therapy company, and bit.bio, the company coding human cells for novel cures, have announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics.

Researchers reported a proteogenomic approach to investigate fresh solid melanoma tumor material.

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that The Lancet Infectious Diseases published results from the company's OVX836-003 study under the title, "Immunogenicity, safety and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: randomized, double-blind placebo-controlled, Phase 2a trial."

In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of cancer cells.